MAP2K4 and glaucoma: Furthermore, identifying the upstream activators of MKK4/7 in the context of glaucoma-relevant injury and elucidating the DDIT3/JUN-independent downstream effectors of MKK4/7 driving loss of somal viability and axonal degeneration will be important next lines of investigation.